Invesco's RSPH vs. PJP: Which Health Care ETF Is the Better Fund For The GLP-1 Revolution?

The Invesco Pharmaceuticals ETF (PJP) is positioned as the stronger 2026 pick, with a 1-year return of 40.20% versus 11.12% for the Invesco S&P 500 Equal Weight Health Care ETF (RSPH). PJP also leads on 5-year performance ($1,469 vs. $1,152 on a $1,000 investment) and has a lower max drawdown of 17.5% versus 22.0%, though RSPH is cheaper at a 0.40% expense ratio versus 0.57%. The piece is primarily a comparative ETF analysis, with limited direct market-moving impact.

Analysis

The real trade is not “healthcare vs pharmaceuticals” but beta compression inside the healthcare complex. PJP is effectively a levered expression on the GLP-1 winner-take-most cycle: capital is flowing toward the names with visible earnings revision momentum, and that favors a small set of drug innovators while starving insurers and slower-growth care providers of multiple expansion. RSPH’s equal-weight structure looks diversified, but it dilutes exposure to the one sub-theme with the strongest incremental capital inflow and leaves investors with more rate-sensitive, reimbursement-sensitive businesses that can lag even in a positive sector tape.

Second-order, the market is rewarding balance-sheet and R&D optionality more than pure defensive healthcare characteristics. CORT’s inclusion matters because it is one of the few mid-cap names with idiosyncratic upside that can offset headline risk in the broader ETF; that makes the pharmaceutical basket more “selection alpha” than sector beta. Conversely, the insurer sleeve embedded in the broader fund is vulnerable if investors continue rotating out of cash-yielding, regulated growth into secular obesity/metabolic winners over the next 6-12 months.

The main risk to the PJP-led view is valuation air-pocketing if GLP-1 enthusiasm stalls or if trial/regulatory headlines disappoint. Because the move has already outperformed on a 1-year basis, the next leg needs earnings delivery, not just narrative. If growth estimates for the top drug names stop inflecting, the concentrated fund can de-rate faster than the broader fund even with lower measured volatility, especially if positioning is crowded and passive flows chase yesterday’s winners.

Consensus may be underestimating how much of this trade is driven by factor exposure, not just sector exposure. PJP’s screen rewards momentum and earnings growth, which means it can continue outperforming even if the sector stops rallying broadly, as long as revisions stay positive. The flip side is that equal-weight healthcare could work as a mean-reversion trade if GLP-1 leadership narrows and insurers or managed care rerate on benign utilization trends.

Key Decisions for Investors

• Long PJP / short RSPH for a 3-6 month relative-value trade: express continued GLP-1 leadership and earnings-revision momentum; stop if pharma breadth breaks and the pair underperforms by ~5-7%.
• Buy CORT on pullbacks as a single-name growth optionality trade with asymmetric upside over 6-12 months; position size modestly because execution risk is higher than large-cap pharma.
• Use RSPH as a hedge only, not a core healthcare bullish vehicle: if owning managed care or hospital names elsewhere, RSPH can offset sector drawdown but will likely lag in a momentum-led tape.
• If entering PJP, do so on weak biotech/pharma days rather than chasing strength; the thesis is revision persistence, so a better entry is after a 2-4% sector selloff with GLP-1 headlines still intact.
• For options traders, consider a 6-month call spread on PJP to capture upside while capping valuation risk; risk/reward is better than outright long because the trade’s main failure mode is multiple compression, not business deterioration.